Filing Analysis
Whitehawk Therapeutics, Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2026. The filing serves as a formal announcement of the earnings release issued on August 6, 2026.
📋 Key Facts
- The company announced financial results for the quarter ending June 30, 2026.
- The report was filed on August 6, 2026.
- The filing includes a press release as Exhibit 99.1.
Whitehawk Therapeutics reported the voting results from its annual meeting of stockholders held on June 11, 2026. The meeting covered the election of Class III directors, advisory approval of executive compensation, and the ratification of BDO USA, P.C. as the independent auditor.
📋 Key Facts
- Annual meeting held on June 11, 2026, with 40,375,023 shares present (approx. 82% of voting power).
- Three Class III directors (Behzad Aghazadeh, Ph.D., Richard Maroun, and Emma Reeve) were elected.
- Executive compensation for named officers was approved on an advisory basis (22,896,061 For vs 6,013,600 Against).
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics, Inc. announced an option agreement with Hangzhou DAC Biotechnology to expand its antibody drug conjugate (ADC) pipeline. The agreement provides Whitehawk with access to the linker-payload CPT113 for up to five additional ADC programs.
📋 Key Facts
- Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC Biotechnology on or before May 21, 2026.
- The agreement grants access to the linker-payload CPT113 for use in up to five additional ADC programs.
- Hangzhou DAC is presenting data for DXC006, which utilizes the CPT113 linker-payload, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Whitehawk Therapeutics announced a $87.5 million PIPE financing through the sale of common stock and pre-funded warrants. The transaction includes significant participation from company insiders and affiliated funds, who committed approximately $39.75 million of the total capital.
🚩 Red Flags
- Significant related-party transaction with insiders and affiliated funds contributing 45% of the total financing.
- Substantial potential dilution from the issuance of over 17.9 million pre-funded warrants.
📋 Key Facts
- Total PIPE financing of $87.5 million consisting of 4,330,866 shares of common stock and 17,991,021 pre-funded warrants.
- Common stock priced at $3.92 per share; pre-funded warrants priced at $3.9199 with a $0.0001 exercise price.
- Insiders, including executive officers and affiliated funds of directors, committed $39,750,000 to the offering.
- The company must file a resale registration statement within 30 days of closing and seek effectiveness within 60-90 days.
- Executive officers and directors are subject to a 60-day lock-up period following the closing.
- Placement agents include Jefferies LLC, Leerink Partners LLC, and Oppenheimer & Co. Inc.
Whitehawk Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release and filed under Item 2.02 of Form 8-K.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Press release issued on May 7, 2026
- Filing signed by Chief Financial Officer Scott Giacobello
- Information is furnished under Item 2.02 and not deemed 'filed' for Section 18 liability
Whitehawk Therapeutics, Inc. (WHWK) filed an 8-K on March 12, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The results were disclosed via a press release attached as Exhibit 99.1. This filing is a standard disclosure under Item 2.02.
📋 Key Facts
- Company reported results for the fiscal year ended December 31, 2025.
- The report was filed on March 12, 2026.
- The filing was signed by Scott Giacobello, Chief Financial Officer.
Whitehawk Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The company's common stock is listed on the Nasdaq Stock Market LLC under ticker WHWK.
Whitehawk Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Whitehawk Therapeutics, Inc. reported the results of its annual meeting of stockholders held on June 11, 2025. The meeting included the election of three Class II directors and the ratification of BDO USA, P.C. as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 11, 2025, with a quorum representing ~61% of voting power (28,690,008 shares).
- Three Class II directors were elected: Anupam Dalal, M.D., Mohammad Hirmand, M.D., and David Lennon, Ph.D.
- The authorized number of directors was decreased from ten (10) to nine (9) effective upon the opening of polls.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The record date for the meeting was April 17, 2025.
Whitehawk Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025.
📋 Key Facts
- The company issued a press release on May 8, 2025, regarding quarterly financial results.
- The reporting period covered the quarter ending March 31, 2025.
- The filing includes Exhibit 99.1 containing the full press release.
Whitehawk Therapeutics, Inc. filed an 8-K/A to amend a previous filing regarding the divestiture of 100% of its subsidiary, Aadi Subsidiary, Inc. The amendment provides required pro forma financial information following the sale to KAKEN INVESTMENTS INC., KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc.
🚩 Red Flags
- Divestiture of a 100% subsidiary often indicates a significant shift in business model or a need for immediate liquidity/restructuring.
📋 Key Facts
- The company completed the sale of 100% of the outstanding shares of its subsidiary, Aadi Subsidiary, Inc. (the 'Divestiture').
- The divestiture was executed pursuant to a Stock Purchase Agreement dated December 19, 2024.
- The buyers in the transaction were KAKEN INVESTMENTS INC., KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc.
- This filing (8-K/A) is specifically intended to provide unaudited pro forma condensed consolidated financial information as of and for the fiscal year ended December 31, 2024.
Whitehawk Therapeutics, Inc. has completed the sale of 100% of its subsidiary, Aadi Subsidiary, Inc., to KAKEN INVESTMENTS INC. and KAKEN PHARMACEUTICAL CO., LTD. The transaction resulted in a cash inflow of $102.4 million.
🚩 Red Flags
- Divestiture of a subsidiary may represent a significant shift in the company's core business model or pipeline focus.
📋 Key Facts
- Completed sale of 100% of outstanding shares of Aadi Subsidiary, Inc. on March 25, 2025.
- Purchaser: KAKEN INVESTMENTS INC., a Delaware corporation, and KAKEN PHARMACEUTICAL CO., LTD.
- Cash consideration received: $102.4 million (after applicable purchase price adjustments).
- The transaction was originally announced via an 8-K filed on December 20, 2024.
Aadi Bioscience, Inc. (now Whitehawk Therapeutics, Inc.) announced its fiscal year 2024 financial results and a formal name change from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc.
🚩 Red Flags
- Name change often occurs during rebranding or restructuring phases in micro-cap biotech companies.
📋 Key Facts
- Company changed its legal name to Whitehawk Therapeutics, Inc. via Board approval on March 18, 2025.
- The name change was filed with the Secretary of State of Delaware and did not require stockholder approval.
- Released financial results for the fiscal year ended December 31, 2024.
- Amended and restated bylaws were adopted to reflect the new corporate name.
Aadi Bioscience successfully closed a PIPE financing and received stockholder approval for several major restructuring items, including the divestiture of its FYARRO business assets to KAKEN INVESTMENTS INC. The company also amended its 2021 Equity Incentive Plan to significantly increase available share reserves.
🚩 Red Flags
- Significant dilution: Approval of issuance of over 21 million new shares via PIPE financing.
- Major asset divestiture: The sale of substantially all assets related to the FYARRO business suggests a fundamental shift in company strategy or a need for liquidity.
- Increased equity compensation pool: Significant increase in share reserve (from 2M to 8.3M) further increases potential dilution.
📋 Key Facts
- Closed PIPE Financing on March 4, 2025.
- Stockholders approved the sale of Aadi Subsidiary, Inc. (FYARRO Business) to KAKEN INVESTMENTS INC.
- Approved issuance of ~21.6M common shares and warrants at $2.40/$2.3999 per share via PIPE Financing.
- Amended 2021 Equity Incentive Plan, increasing available shares from ~2M to ~8.3M.
- Stockholders approved 'Golden Parachute' compensation for named executive officers related to the divestiture.
Aadi Bioscience has entered into a definitive agreement to be acquired by Kaken Investments Inc. for $100 million, representing a significant liquidity event and exit strategy for the company.
🚩 Red Flags
- Significant termination fee ($3.5M) if the board changes its recommendation or accepts a superior proposal.
- Non-compete restriction limits Aadi's business activities for 4 years post-closing.
- Deal is subject to stockholder approval and regulatory clearances.
📋 Key Facts
- Acquisition price: $100,000,000 (subject to customary adjustments for cash, debt, NWC, and expenses).
- Purchaser: Kaken Investments Inc. (with Kaken Pharmaceutical Co., Ltd. acting as Guarantor).
- Structure: Purchaser will acquire 100% of the outstanding shares of Aadi's subsidiary (Private Aadi).
- Stockholder Support: Directors, executive officers, and a significant stockholder have signed support agreements covering ~36% of common stock.
- Termination Fee: $3,500,000 payable by Aadi to Purchaser under specific circumstances (e.g., superior proposal or change in board recommendation).
- Closing Deadline: Expected by June 30, 2025, with a possible extension to September 30, 2025.
- Restrictive Covenant: Aadi is subject to a non-compete/restrictive covenant for four years following closing.
Aadi Bioscience, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 6, 2024.
Aadi Bioscience announced that an arbitration panel issued a Final Award on September 26, 2024, regarding a dispute with EOC Pharma (Hong Kong) Limited. The panel ruled in favor of the Company, finding no breach of the December 8, 2020 license agreement and determining the Company is not liable for damages.
📋 Key Facts
- Arbitration was initiated by EOC Pharma (Hong Kong) Limited in June 2022 via the International Chamber of Commerce’s International Court of Arbitration.
- EOC's claim alleged breaches of a license agreement dated December 8, 2020, specifically regarding failure to provide manufacturing information.
- The Final Award issued on September 26, 2024, concluded the Company did not breach the agreement.
- The Company is not liable for any monetary damages sought by EOC.
Aadi Bioscience announced the implementation of a retention bonus program for its CEO, Dr. David J. Lennon, and CFO, Scott Giacobello. The bonuses are contingent upon their continued employment through March 31, 2025, or until a Change of Control event.
🚩 Red Flags
- Retention bonuses often signal management instability or an imminent strategic shift/sale (Change of Control context).
- The inclusion of 'Change of Control' as a trigger for bonus payment suggests the company may be positioning itself for a merger or acquisition.
📋 Key Facts
- Retention bonus of $390,000 approved for CEO David J. Lennon.
- Retention bonus of $220,000 approved for CFO Scott Giacobello.
- Bonus eligibility requires employment through March 31, 2025, or a Change of Control event.
- Severance provisions are included if terminated without Cause, death, disability, or resignation for Good Reason.
Aadi Bioscience announced the voluntary resignation of its Chief Medical Officer, Dr. Loretta Itri, and the departure of Executive Chairman Neil Desai, both effective October 1, 2024.
🚩 Red Flags
- Simultaneous departure of two high-level executives (CMO and Executive Chairman) within the same month.
- Loss of key medical leadership (CMO) is often a concern for clinical-stage biotech companies.
📋 Key Facts
- Dr. Loretta Itri (CMO) is resigning voluntarily, effective October 1, 2024.
- Dr. Itri will receive 12 months of severance (base salary + full 2024 target bonus divided by 12) and 18 months of COBRA reimbursement.
- A consulting agreement was approved for Dr. Itri: 10 hours/month at an $8,000 monthly retainer for an initial three-month term.
- Dr. Neil Desai (Executive Chairman) will cease employment as Executive Chairman on October 1, 2024, but will remain a member of the Board.
- Both departing executives will continue to vest in outstanding equity awards during their respective transition/board roles.
Aadi Bioscience announced a significant workforce reduction of 22 employees, representing approximately 32% of its total headcount. The company expects to incur non-recurring charges between $2.2 million and $2.5 million related to this termination plan.
🚩 Red Flags
- Significant workforce reduction (32% of staff) often indicates a need for immediate cash preservation or a pivot in strategy.
- Non-recurring charges of $2.2M-$2.5M represent a material impact on the current quarter's financial results.
📋 Key Facts
- Workforce reduction involves 22 employees (approx. 32% of workforce).
- Estimated non-recurring charges: $2.2M - $2.5M.
- Charges primarily consist of severance, benefits, and related costs.
- Majority of charges expected in Q3 2024; completion by end of Q4 2024.
- Interim efficacy results from the PRECISION1 Phase 2 trial were released via press release on August 20, 2024.
Aadi Bioscience, Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2024.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is a standard announcement of quarterly results via press release (Exhibit 99.1).
Aadi Bioscience, Inc. held its annual meeting of stockholders on June 11, 2024. The company reported voting results for the election of directors, advisory compensation votes, and the ratification of their independent auditor.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Quorum reached with 15,104,613 shares (approx. 62% of voting power) present in person or by proxy.
- Caley Castelein and Neil Desai were elected to the Class I Board of Directors.
- Shareholders approved the appointment of BDO USA LLP as independent auditor for fiscal year ending Dec 31, 2024.
- Advisory vote on executive compensation (Say-on-Pay) was passed with 8,971,541 votes in favor.
Aadi Bioscience, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard announcement of quarterly results via press release (Exhibit 99.1).
Aadi Bioscience entered into an amendment to its existing supply agreement with Fresenius Kabi, LLC. The amendment extends the term of the agreement until July 31, 2024, and revises terms regarding pricing, forecasting, and minimum purchase obligations for FYARRO®.
🚩 Red Flags
- Short-term nature of the extension (only through July 31, 2024) suggests potential uncertainty in long-term supply or commercial partnership stability.
- Revised 'minimum quantity' obligations may place additional financial/inventory pressure on the company.
📋 Key Facts
- Entered into Amendment No. 2 to the Negotiated Purchase Order Terms and Conditions with Fresenius Kabi, LLC on April 1, 2024.
- The amendment is effective as of March 31, 2024.
- Agreement term extended until July 31, 2024 (with possibility of further extension).
- Revised terms include pricing, forecasting, compliance, and minimum purchase quantities for FYARRO®.
Aadi Bioscience, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal notice that the company has released its annual earnings press release.
📋 Key Facts
- Company announced fiscal year 2023 financial results on March 13, 2024.
- The filing includes an attachment (Exhibit 99.1) containing the full press release of the financial results.
- Signed by Scott Giacobello, Chief Financial Officer.